Clinical Trial

A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-21.
Status change: Not Yet Recruiting → Recruiting 2024-12-09
Trial Details
NCT Number NCT06654440
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced Gynecological Malignancy
Enrollment 100 participants
Start Date 2024-11-15
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-10